BidaskClub upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a strong sell rating to a sell rating in a research note published on Saturday morning, BidAskClub reports.

AMPH has been the subject of a number of other reports. TheStreet lowered Amphastar Pharmaceuticals from a b- rating to a c rating in a research report on Thursday, November 7th. Zacks Investment Research lowered Amphastar Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, October 24th. Finally, ValuEngine upgraded Amphastar Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $24.05.

Shares of AMPH stock opened at $19.99 on Friday. The stock has a 50-day moving average price of $19.27 and a 200 day moving average price of $19.93. The company has a quick ratio of 1.84, a current ratio of 3.11 and a debt-to-equity ratio of 0.13. The firm has a market cap of $944.43 million, a price-to-earnings ratio of 19.04 and a beta of 1.16. Amphastar Pharmaceuticals has a 12 month low of $16.71 and a 12 month high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.10 EPS for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.02. The firm had revenue of $80.14 million during the quarter, compared to analyst estimates of $78.53 million. Amphastar Pharmaceuticals had a return on equity of 5.07% and a net margin of 15.77%. The company’s revenue was up 6.1% on a year-over-year basis. During the same period last year, the company earned $0.12 earnings per share. Sell-side analysts predict that Amphastar Pharmaceuticals will post 0.05 earnings per share for the current fiscal year.

In other Amphastar Pharmaceuticals news, General Counsel Jason B. Shandell sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $18.44, for a total transaction of $461,000.00. Following the transaction, the general counsel now owns 163,898 shares in the company, valued at $3,022,279.12. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, General Counsel Jason B. Shandell sold 8,205 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $19.13, for a total value of $156,961.65. Following the transaction, the general counsel now owns 138,898 shares in the company, valued at approximately $2,657,118.74. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,205 shares of company stock worth $656,467. Company insiders own 30.80% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of AMPH. JPMorgan Chase & Co. boosted its holdings in Amphastar Pharmaceuticals by 15.4% during the second quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock worth $205,000 after buying an additional 1,314 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Amphastar Pharmaceuticals by 16.1% during the second quarter. Russell Investments Group Ltd. now owns 22,400 shares of the company’s stock worth $472,000 after buying an additional 3,100 shares during the last quarter. Bank of Montreal Can boosted its holdings in Amphastar Pharmaceuticals by 130.7% during the second quarter. Bank of Montreal Can now owns 4,923 shares of the company’s stock worth $104,000 after buying an additional 2,789 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Amphastar Pharmaceuticals by 11.9% during the second quarter. Charles Schwab Investment Management Inc. now owns 212,178 shares of the company’s stock worth $4,480,000 after buying an additional 22,618 shares during the last quarter. Finally, LPL Financial LLC bought a new position in Amphastar Pharmaceuticals during the second quarter worth about $312,000. Hedge funds and other institutional investors own 51.27% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Story: How can investors find ex-dividend dates?

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.